Gilead Sciences agrees to $246.8M settlement in HIV drug antitrust case: Scam or Legit? Find Out!

Did you receive a mail about a class action settlement concerning Gilead Sciences agreeing to $246.8M settlement in HIV drug antitrust case? This review will help you partake in the class action settlement after confirming the authenticity of the mail.

What Is Gilead Sciences agreeing to $246.8M settlement in HIV drug antitrust case lawsuit?

Gilead Sciences agreed to pay $246.8 million to settle a class action lawsuit direct purchasers of its HIV medications filed. The Gilead Sciences lawsuit was filed in California federal court.

The plaintiffs alleged Gilead made a deal with Teva Pharmaceuticals to delay generic versions of the drugs, causing buyers to pay inflated prices.

Direct purchaser class members are represented by the Law Offices of Francis O. Scarpulla, NastLaw LLC, Roberts Law Firm US PC and Hausfeld LLP.

The case is In re: HIV Antitrust Litigation, Case No. 3:19-cv-02573, in the U.S. District Court for the Northern District of California.

What Is This Class Action All About?

Gilead Sciences reached a $246.8 million class action lawsuit settlement with direct purchasers of its HIV medications over allegations it made a deal with Teva Pharmaceuticals to delay generic versions of the drugs, Law360 reports.

On Aug. 9, the direct purchaser plaintiffs filed a motion in California federal court seeking preliminary approval of the Gilead Sciences settlement resolving allegations they overpaid for HIV drugs Atripla and Truvada between February 2018 and September 2022.

The motion states the parties reached the settlement after “years of hard-fought litigation” and negotiations. They reportedly reached a final agreement July 24.

The direct purchasers originally sought about $2 billion in their Gilead Sciences lawsuit. The proposed settlement would cover approximately 12% of their estimated damages.

The plaintiffs say this recovery is significant “given the relatively high risks of no recovery or a substantially reduced recovery.”

The trial would have involved claims from direct buyers and four other groups of plaintiffs with “sometimes diverging interests and trial strategies,” increasing the risk of little to no recovery for the direct purchasers, the motion says.

Who Is Eligible?

This settlement concerns all persons whose affected by the proposed Gilead Sciences settlement.

How To Be Part of This Settlement

To partake in this settlement, class member must submit a valid and timely claim on the settlement website.

What Is The Pay For This Settlement?

The pay for this settlement varies and the proof of purchase is not necessary.


As you submit your claim to the settlement website, just like class action settlement we have reviewed, you’re doing so under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim.

Leave a Comment

error: Content is protected !!